Research & News

Is Compounded Semaglutide Legal in 2026

6 min read · Published 2026-04-16 · Sources cited to FDA / NIH / clinical trials

As of 2026, compounded semaglutide exists in a significantly restricted legal gray zone. The FDA declared the semaglutide shortage officially resolved in February 2025, which triggered a phased wind-down period for compounding. Most compounded semaglutide — whether from 503A pharmacies or 503B outsourcing facilities — is no longer broadly permitted, though narrow legal exceptions still exist in specific circumstances.

What Changed After the FDA Resolved the Semaglutide Shortage?

Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are allowed to produce copies of FDA-approved drugs when those drugs appear on the official shortage list. Ozempic and Wegovy appeared on that list beginning in 2022 and 2023, respectively, which opened the door for widespread compounded semaglutide production.

In February 2025, the FDA announced it had resolved the shortage of semaglutide injection products, removing them from the shortage list. Under FDA rules, this triggered deadlines for compounders to stop producing the drug:

  • 503B outsourcing facilities (larger, FDA-registered facilities) were given until April 22, 2025 to stop producing and distributing compounded semaglutide.
  • 503A pharmacies (traditional compounding pharmacies filling individual prescriptions) were given until May 22, 2025 to cease production.

Those deadlines have passed. By mid-2025 and into 2026, the large-scale compounding of semaglutide that was common from 2022 to 2025 is no longer legally authorized under the shortage exemption.

Are There Any Legal Exceptions That Still Apply in 2026?

Yes — but they are narrow. The FDA's compounding rules under Section 503A of the FD&C Act still allow a licensed pharmacist to compound a drug for an individual patient if a licensed prescriber determines there is a documented clinical difference needed for that specific patient. Examples include:

  • A patient with a confirmed allergy to an inactive ingredient in the commercially available product.
  • A need for a specific dose or dosage form not available commercially (e.g., a different concentration for a patient with a documented swallowing or absorption issue).

This is a case-by-case, patient-specific exemption — not a blanket permission to dispense compounded semaglutide broadly. Telehealth platforms and compounding pharmacies that continue selling compounded semaglutide without documented clinical necessity are operating outside FDA guidance and may face enforcement action.

Most important takeaway: The shortage exemption that made compounded semaglutide widely available has ended. Unless your prescriber documents a specific medical reason why the FDA-approved product cannot meet your needs, compounded semaglutide is not legally authorized for you in 2026. Purchasing it from platforms that do not verify this puts you at legal and health risk.

Timeline: How Compounded Semaglutide's Legal Status Evolved

Date Event Legal Impact
2022 Ozempic added to FDA shortage list Compounding permitted under 503A/503B shortage exemption
2023 Wegovy added to FDA shortage list Shortage exemption extended to weight-loss indication
2024 FDA issues MedWatch alerts on compounded semaglutide risks No legal change; safety warnings issued to consumers
February 2025 FDA resolves semaglutide shortage Shortage exemption begins wind-down; deadlines set
April 22, 2025 Deadline for 503B outsourcing facilities Large-scale compounded semaglutide production must stop
May 22, 2025 Deadline for 503A pharmacies Individual-prescription compounding must stop (except narrow exceptions)
2026 onward Enforcement phase Only documented patient-specific exceptions permitted; FDA may pursue violators

What Are the Risks of Using Compounded Semaglutide in 2026?

Beyond the legal questions, the FDA has consistently flagged safety concerns about compounded semaglutide. In 2024, the agency issued a MedWatch safety alert noting reports of adverse events — including hospitalizations — linked to compounded semaglutide products. Key risks include:

  • Incorrect dosing: Some compounded products contained different salt forms (such as semaglutide sodium or semaglutide acetate) rather than the base semaglutide used in FDA-approved drugs. These are not bioequivalent and have not been proven safe or effective.
  • No FDA manufacturing oversight: Compounding pharmacies, unlike drug manufacturers, are not required to meet the same Current Good Manufacturing Practice (CGMP) standards for sterile injectables.
  • Labeling errors: The FDA found some compounded products were mislabeled with doses expressed in milligrams rather than units, leading to ten-fold dosing errors.

If you are currently using compounded semaglutide obtained before the deadlines, speak with your prescriber about transitioning to an FDA-approved product.

How Can You Access Semaglutide Legally in 2026?

FDA-approved semaglutide products remain available through standard pharmacy channels with a valid prescription:

  • Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg injection) — approved for type 2 diabetes
  • Wegovy (semaglutide 2.4 mg injection) — approved for chronic weight management
  • Rybelsus (semaglutide 7 mg, 14 mg oral tablet) — approved for type 2 diabetes

Manufacturer patient assistance programs through Novo Nordisk, insurance prior authorization support, and authorized telehealth platforms that prescribe brand-name products are all legitimate pathways. If cost is a barrier, ask your prescriber about the Novo Nordisk Patient Assistance Program or state pharmaceutical assistance programs.

Frequently Asked Questions

Not entirely. It is illegal under the shortage exemption that previously applied broadly. However, 503A pharmacies can still compound it for individual patients when a prescriber documents a specific clinical need not met by the approved product. Widespread dispensing without that documentation is not legally authorized.
Any telehealth platform still offering compounded semaglutide without documenting a patient-specific medical need is operating outside current FDA guidance. You should ask any such platform to explain the legal basis for their compounding and verify the pharmacy's 503A or 503B registration status.
Talk to your prescriber. They can evaluate whether you qualify for a documented exception or help you transition to an FDA-approved product. Do not abruptly stop semaglutide without medical guidance, as this may affect blood sugar control or weight management.
Tirzepatide had its own separate shortage listing and FDA actions. Its compounding status has followed a similar but distinct timeline. Check the FDA drug shortages database for the current status, as it may differ from semaglutide.
Semaglutide sodium and semaglutide acetate are salt forms sometimes used in compounding. They are not the same as the base semaglutide in FDA-approved drugs and have not undergone clinical trials proving they deliver equivalent doses or safety profiles. The FDA has specifically flagged this as a concern.
FDA enforcement actions have historically targeted manufacturers and dispensers, not individual patients. However, using a product that does not meet FDA standards carries real health risks regardless of the legal exposure to you personally.
You can verify 503B outsourcing facilities on the FDA's registered outsourcing facilities list. For 503A pharmacies, check your state board of pharmacy's licensing database.
Only if semaglutide is re-added to the FDA shortage list due to documented supply disruptions. As of 2026, there is no indication that a new shortage designation is imminent.

The regulatory landscape around compounded semaglutide has shifted significantly, and what was widely available and legally permitted in 2023 or 2024 is no longer the case. Your prescriber is the best person to help you understand your specific options, whether that means qualifying for a compounding exception, accessing an FDA-approved product, or exploring financial assistance programs to make brand-name semaglutide more affordable.

Sources
  • FDA Drug Shortages Database, semaglutide injection listing (2023–2025), https://www.accessdata.fda.gov/scripts/drugshortages/
  • FDA Guidance: Compounding and the Drug Supply Chain Security Act
  • FDA Statement on Shortage Resolution for Semaglutide Products (February 2025)
  • Federal Food, Drug, and Cosmetic Act, Section 503A and 503B, 21 U.S.C. §§ 503A, 503B
  • FDA MedWatch Safety Alert: Compounded semaglutide products (2024), https://www.fda.gov/safety/medical-product-safety-information
  • Pharmacy Compounding Advisory Committee (PCAC) Meeting Minutes, 2024

Keep Reading

Ozempic Hair Loss: Why It Happens and How to Stop ItResearch & News · 5 min readSemaglutide (Ozempic / Wegovy / Rybelsus)Drugs · 10 min read

This site provides general information only and does not constitute medical advice. All content is sourced to FDA labeling, NIH publications, or peer-reviewed clinical trials. Always consult your prescriber before making any medication decision.